Numerous studies have investigated aripiprazole as a treatment for bipolar disorder (BD). therefore we conducted this comprehensive meta-analysis to investigate the efficacy and safety profile of aripiprazole in treating BD. Two authors conducted systematic searches of PubMed and ScienceDirect from inception until May 14th, 2017. Randomized controlled trials (RCTs) of people with BD who received aripiprazole were included. A total of 20 RCTs met the eligibility criteria, including two which investigated the efficacy of aripiprazole versus haloperidol (aripiprazole = 340; haloperidol = 337), three which compared aripiprazole versus lithium (aripiprazole = 208; lithium = 212), and 15 with multiple comparisons of aripiprazole versus a placebo (aripiprazole = 1923; placebo = 1499). Compared to a placebo, aripiprazole improved acute mania (Hedges' g: − 0.299, p = 0.001) and psychosis (Hedges' g: − 0.296, p < 0.001) in the acute mania state, but did not improve depressive symptoms (Hedges' g: − 0.127, p = 0.054) in the acute depressive state. Aripiprazole was associated with lower relapse rates in bipolar mania when used in combination versus a placebo in maintenance therapy (odds ratio: 0.522, p < 0.029). Aripiprazole was also associated with higher levels of high density lipoprotein, lower dropout rates, but no difference in extrapyramidal symptoms in the maintenance phase versus a placebo or in comparison with other medications (haloperidol or lithium). Our results suggest that aripiprazole is effective and safe in treating bipolar mania. Further trials are necessary to evaluate the efficacy and tolerability versus other medications. © 2017 Elsevier Inc.

Li, D., Tseng, P., Stubbs, B., Chu, C., Chang, H., Vieta, E., et al. (2017). Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 79, 289-301 [10.1016/j.pnpbp.2017.06.023].

Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials

Veronese, N.;
2017-01-01

Abstract

Numerous studies have investigated aripiprazole as a treatment for bipolar disorder (BD). therefore we conducted this comprehensive meta-analysis to investigate the efficacy and safety profile of aripiprazole in treating BD. Two authors conducted systematic searches of PubMed and ScienceDirect from inception until May 14th, 2017. Randomized controlled trials (RCTs) of people with BD who received aripiprazole were included. A total of 20 RCTs met the eligibility criteria, including two which investigated the efficacy of aripiprazole versus haloperidol (aripiprazole = 340; haloperidol = 337), three which compared aripiprazole versus lithium (aripiprazole = 208; lithium = 212), and 15 with multiple comparisons of aripiprazole versus a placebo (aripiprazole = 1923; placebo = 1499). Compared to a placebo, aripiprazole improved acute mania (Hedges' g: − 0.299, p = 0.001) and psychosis (Hedges' g: − 0.296, p < 0.001) in the acute mania state, but did not improve depressive symptoms (Hedges' g: − 0.127, p = 0.054) in the acute depressive state. Aripiprazole was associated with lower relapse rates in bipolar mania when used in combination versus a placebo in maintenance therapy (odds ratio: 0.522, p < 0.029). Aripiprazole was also associated with higher levels of high density lipoprotein, lower dropout rates, but no difference in extrapyramidal symptoms in the maintenance phase versus a placebo or in comparison with other medications (haloperidol or lithium). Our results suggest that aripiprazole is effective and safe in treating bipolar mania. Further trials are necessary to evaluate the efficacy and tolerability versus other medications. © 2017 Elsevier Inc.
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023645094&doi=10.1016/j.pnpbp.2017.06.023&partnerID=40&md5=483ed0b6bef9e8c10e5be6661b01ab97
Li, D., Tseng, P., Stubbs, B., Chu, C., Chang, H., Vieta, E., et al. (2017). Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 79, 289-301 [10.1016/j.pnpbp.2017.06.023].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0278584617302385-main.pdf

Solo gestori archvio

Tipologia: Versione Editoriale
Dimensione 1.14 MB
Formato Adobe PDF
1.14 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/460302
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 18
social impact